Work

Darunavir Is a Good Third-Line Antiretroviral Agent for HIV Type 1-Infected Patients Failing Second-Line Protease Inhibitor-Based Regimens in South India

Year: 2012
Type: article
Study design: Observational Study
Abstract: Eleven protease mutations have been associated with reduced susceptibility to darunavir. In this study of 87 HIV-1-infected patients experiencing virological failure to second-line regimens containing protease inhibitors boosted with ritonavir (viral load >1,000 HIV RNA copies/ml), we observed a low prevalence (3%) of ≥3 darunavir resistance-associated mutations, indicating that this drug may be a good option for third-line antiretroviral therapy in southern India.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W2005160929
FWCI: 0.66
Cites: 13
Cited by: 7
Related to: 9